Immunotherapy of type 1 diabetes: where are we and where should we be going? - Wikidata - wikimedia - TriplyDB

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Immunotherapy of type 1 diabetes: where are we and where should we be going?

http://www.wikidata.org/entity/Q33815506

about

Immunotherapy in autoimmune type 1 diabetes Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation.Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.Surrogate insulin-producing cells.Functional alterations of proinflammatory monocytes by T regulatory cells: implications for the prevention and reversal of type 1 diabetes.Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice.Have we overestimated the benefit of human(ized) antibodies?GPS-MBA: computational analysis of MHC class II epitopes in type 1 diabetes Treg vaccination with a strong-agonistic insulin mimetope.ACE2 and diabetes: ACE of ACEs?Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach Treg vaccination in autoimmune type 1 diabetes.A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.Juvenile Diabetes Research Foundation: mission, strategy, and priorities Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.Proteomic Analysis of Disease Stratified Human Pancreas Tissue Indicates Unique Signature of Type 1 Diabetes Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35.Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.Mechanistic basis of immunotherapies for type 1 diabetes mellitus Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model.PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.Regulatory T cells control diabetes without compromising acute anti-viral defense.Recovery from overt type 1 diabetes ensues when immune tolerance and β-cell formation are coupled with regeneration of endothelial cells in the pancreatic islets.DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1 Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment Refractory rheumatoid factor positive polyarthritis in a female adolescent already suffering from type 1 diabetes mellitus and Hashimoto's thyroiditis successfully treated with etanercept Inducing immune tolerance: a focus on Type 1 diabetes mellitus.CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes.

P2860

Q27025619-6F36022E-9A1D-4662-8457-AA7C0F8A6381 Q27334532-229C00B7-0FF2-43D6-8E3F-1E815BF255D8 Q30430008-4EFE4053-D8C3-48E1-84D7-C047C7C699B1 Q34024395-2B92A385-EEB1-415E-89A7-DE29303A326D Q34033127-DE5DDDE8-F2DF-4CE7-9459-A834204ADD32 Q34072307-61E21892-700F-4555-B0E1-4993E03A43E8 Q34089896-6D9D897D-6A02-4CDA-9691-75F0D03B7AEC Q34142714-3C503FF3-5D4C-4B9E-954D-F01D667DAE86 Q34221724-AED17A70-D95C-48E0-AC37-DB76B5C30F51 Q34327132-85256507-A493-4F42-B2F6-A00723E63044 Q34355126-2457652A-7502-4183-A400-C191C6A25254 Q34355286-45939664-3855-4566-BDA9-FAAA8AC88E1F Q34706913-69F6D00C-A5E6-419C-8792-00EC874C4353 Q34718795-ADD827C8-AC08-4B4E-846E-4F29EBE386E8 Q34957397-45503D28-D208-44F6-AD24-A00A6AD7D6CA Q34972123-CA950CE3-9667-4EC5-9FBA-F0C4A014135C Q35321191-EF1B5F2B-E503-4F53-8D63-0A078DB714FC Q35612407-6621D217-1518-4036-9B8D-83BB4776DACB Q35716720-1A0F6B71-8DBE-4F19-B78B-24B054D065A9 Q35753856-68EA97FB-C6AC-4793-8DD6-C36CFA5BCC6E Q35913697-EE170D9C-BEEE-407A-BF04-0006691717C9 Q35976614-6C341492-6A4B-4774-A7F6-1CBCD38CD324 Q35976619-94A00254-765B-4CD1-BB28-9D19CB6553EC Q35976659-01959BA2-2286-40AE-831D-8FAD808DC069 Q36209928-5F69E66D-BD0E-486F-9676-6904E56AA943 Q36292592-A50EDF7A-2E26-4902-B6BF-E757B7EAEBB0 Q36632019-5B522B43-ECD2-44DC-8265-BF60FCD1B6EE Q36637650-69BA17F3-D17B-4425-A5FA-5D7B4218FE71 Q36640081-CA136B2C-289B-4B24-B69C-AE3E5A115B6E Q36661068-70A3D7DA-8DD4-40A4-BAB7-92B2D58E7956 Q36698793-2D8491EE-F633-4ED8-8742-5091842B5B86 Q36741859-7F939457-0B03-45F9-9F94-8F610BD804B2 Q36801593-DC95F6C7-5D2B-43C5-BA46-8024AF52B502 Q36957509-0CFCE53A-C474-4E5B-90E7-0BC75F0A8CD3 Q37030992-9EBB5F36-CA13-49A2-B238-5BD90C1C703F Q37249892-E02521A7-2923-4F36-8670-711EB612CA16 Q37263111-AD0FE41C-637A-4277-B79E-5C4F2B5372D0 Q37368232-A473662B-1170-4744-9CD6-160111A1228E Q37542678-F16D27CC-84A5-4F17-9D3F-8611FAA2D22D Q37613441-6617F143-9A34-476B-B906-553A7C89C32B

P2860

Immunotherapy of type 1 diabetes: where are we and where should we be going?

http://www.wikidata.org/entity/Q33815506

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@ast

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@en

type

label

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@ast

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@en

prefLabel

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@ast

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@en

P1433

Q33815506-787CC14D-4257-406D-9C1D-1ABAF781B457

P1476

Q33815506-96D3F4BB-045E-4D86-BFB2-5C420441520C

P2093

Q33815506-57EF3AED-5000-4C65-A9C0-1107F2DB3B03

Q33815506-6A87298F-A27F-4A66-BDF3-6966A5358214

Q33815506-B58DA98A-BC8C-46EE-8CCB-8FAC52ED0342

P2860

Q33815506-003DFA13-7B3A-4E73-BA1D-9C55C99AF06A

Q33815506-034903EE-1D0D-4AE1-BE1B-38AE47F8555D

Q33815506-07266A32-1C8D-43F1-B08B-7659AB129F7E

Q33815506-09D83AE7-C9B2-44F4-8C01-EE730E1444EB

Q33815506-0E07CA09-4A78-4B7F-AAD8-24BCEE0E669A

Q33815506-161F9924-DFC6-461E-B657-6396A5978573

Q33815506-19E06759-739C-4AB8-8D88-1CC0D47D5A59

Q33815506-1D6993BE-AF2A-426F-8D39-6DE5631C95C1

Q33815506-1DAA5A24-615B-450A-B0D3-EA863D2D812D

Q33815506-1E6444BB-8BD3-4721-A3FB-63AE9F64AE0D

P304

Q33815506-80BEBC62-ABE3-42AF-9637-EF98775C47B8

P31

Q33815506-376E3ED1-0C92-409E-A483-8A72E294EE64

P356

Q33815506-5B82EB19-3A9D-4F0E-A281-D15CCBFAB30A

P407

Q33815506-94932A90-BE17-4D8B-B7DB-8871FFA1D2F7

P433

Q33815506-1C29ADF4-775B-4314-B4ED-03EB752C7F95

P478

Q33815506-F2B3ABF5-BA3B-48E7-8975-BAE39088A6F9

P577

Q33815506-C5109084-A8BF-4BEB-9BFC-AE45DB9A3F62

P5875

Q33815506-94BCEAC5-2D6F-40CF-8B39-CA69DD6BDD35

P698

Q33815506-9DBB7D11-DB50-403C-A2BD-DBDDFAF2A33F

P921

Q33815506-B6708D9F-C068-4D24-972C-1FDE5FFC6A85

Q33815506-EF7B6ED9-2D0C-4560-A77A-3F1D12C57060

P932

Q33815506-3D22F47E-1051-489B-9689-332E4CFE1016

P356

J.IMMUNI.2010.04.002

P1433

P1476

Immunotherapy of type 1 diabetes: where are we and where should we be going?

@en

P2093

Kevan C Herold

http://www.w3.org/2001/XMLSchema#string

Stephen D Miller

http://www.w3.org/2001/XMLSchema#string

Xunrong Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

Genetics of type 1A diabetes.

Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.

Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes.

Nicotinamide in type 1 diabetes. Mechanism of action revisited.

Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

The NOD mouse model of type 1 diabetes: as good as it gets?

P304

488-499

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IMMUNI.2010.04.002

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43298385

http://www.w3.org/2001/XMLSchema#string

P698

20412759

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

2860878

http://www.w3.org/2001/XMLSchema#string